Aura Biosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Aura Biosciences reports a wider 2025 net loss, substantial doubt about going concern, active late‑stage bel-sar program under SPA, and recent/warranted financings to extend runway.
NASDAQ
Aura Biosciences files its 10-K, reporting a net loss for 2024 while highlighting the ongoing Phase 3 trial of Bel-Sar and its potential across multiple oncology indications.
NASDAQ
10-K/A: Aura Biosciences Amends Annual Report to Update Executive Compensation and Ownership Details
Aura Biosciences has filed an amendment to its annual report to update executive compensation details and beneficial ownership information.
NASDAQ
Aura Biosciences' 10-K filing outlines the company's registered securities, registration rights, anti-takeover measures, and other corporate governance details.